Inclusion criteria:

1. Women who are 18 to 50 years of age and not post-menopausal (i.e., 12 consecutive months of amenorrhea) at the Screen Visit.
2. Women with mild or remitted depressive disorder (may also have concurrent mild anxiety disorder or premenstrual dysphoric disorder) supported by a score of <'11' on the Quick Inventory of Depressive Symptoms Self Report 16 and <'16' on the Beck Anxiety Inventory at Screen and Baseline Visits.
3. Women must have decreased sexual desire and distress that has been present for at least four weeks at Screen Visit as determined by the Clinical Interview for Female Sexual Dysfunction - Depression and Diagnostic and Statistical Manual IV-Text Revision criteria.
4. A score of '15' or higher on the Female Sexual Distress Scale-Revised at the Screen and Baseline Visits.
5. A score of '9' or lower on the Changes in Sexual Functioning Questionnaire-Female desire/interest item at the Screen and Baseline Visits.
6. Patients must be taking the same Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor for three months and be on a stable dose for at least two months before the Screen Visit and plan to remain on this same Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor through out the trial and for one month after the completion of the trial.
7. Patients must have had no treatment for Female Sexual Dysfunction in the two months before the start of the Screen Visit.
8. Patients must use a medically acceptable method of contraception.
9. Patients must be in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least twelve months prior to the Screen Visit, according to the Clinical Interview for Female Sexual Dysfunction - Depression. The relationship is to be with the same partner who is sexually functional, both psychologically and physically, and the partner is expected to be physically present.

Exclusion criteria:

Clinically relevant conditions which might interfere with the patient's ability to participate in the trial include, but are not limited to the following:

1. Patients who have taken any Prohibited Medications, within 30 days before the Baseline Visit.
2. Patients with a history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual IV-Text Revision or in the opinion of the investigator) within the past 12 months.
3. Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin.
4. Women with lifelong: decreased sexual desire (or Hypoactive Sexual Desire Disorder), Female Sexual Arousal Disorder and/or Female Orgasmic Disorder, according to Diagnostic and Statistical Manual IV-Text Revision criteria.
5. Patients who meet Diagnostic and Statistical Manual IV-Text Revision criteria for Sexual Aversion Disorder, Substance-Induced Sexual Dysfunction other than Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction, Dyspareunia (not caused by inadequate foreplay stimulation or alleviated by lubricants), Vaginismus, Gender Identity Disorder, Paraphilia, or for Sexual Dysfunction Due to a General Medical Condition other than Sexual Dysfunction Due to Depression.
6. Patients who have had a hysterectomy (with or without bilateral oophorectomy), or are in the post menopause stage (i.e., had bilateral oophorectomy or have chemical induced [e.g., chemotherapy] menopause).
7. Patients with a history of pelvic inflammatory disease, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy in the preceding four weeks before the Screen Visit.
8. Patients who are breastfeeding or have breastfed within the six months prior to the Baseline Visit.
9. Patients who are pregnant (by serum pregnancy test at the Screen Visit) or have been pregnant within the six months prior to the Baseline Visit.
10. Patients with a current episode of Depressive Disorder (may also have concurrent mild Anxiety Disorder) not adequately controlled during the last two months and/or with a score of <11 on the Quick Inventory of Depressive Symptoms Self Report 16 and/or a score of <16 on the Beck Anxiety Inventory at Screen and/or Baseline Visits.
11. Patients with a history of suicide attempt within the last 12 months or currently active suicidal ideation. The investigator must assess the patient's history of suicide attempt/ideation and determine if the patient is "at risk" before entering the trial.
12. Patients with a history of any other psychiatric disorders that could impact sexual function, risks patient's safety, or may impact compliance. Axis I disorders (except anxiety symptoms and disorders) including eating disorders are excluded. Axis II disorders (except mental retardation and anti-social personality disorder) are allowed.
13. Patients with clinically significant cardiac, neurologic, hepatic, renal, hematologic, respiratory, gastrointestinal, immunological, and endocrine disease.
14. Patients with a history of breast cancer and/or other cancer within the last 5 years, other than non-invasive, previously resected skin cancer.